Nanomerics NM127 Intranasal Enkephalin licensed to be developed by Virpax for PTSD

Nanomerics has signed a technology license agreement withVirpax® Pharmaceuticals Inc. ("Virpax"), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems.  Virpax has acquired exclusive global rights to use Nanomerics' NM127 and its Naltos Nasal delviery Device for the management of Post-Traumatic Stress Disorder (PTSD). The agreement expands on an earlier agreement in which Virapx acquired a license to the NM127 Nalots combination product for the treatmen of pain. Virpax and Nanomerics will validate proof-of-concept followed by IND-enabling studies for the development of its novel enkephalin-based formulation to treat Post-Traumatic Stress Disorder.  "We are delighted to be collaborating with Virpax Pharmaceuticals in the development of a product to treat PTSD," said Nanomerics' Chief Scientific Officer, Professor Ijeoma F. Uchegbu. "We look forward to working with Virpax to bring these innovative new treatments to patients."

Share this post